Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IOB - Delayed Quote EUR

Faes Farma, S.A. (0K9H.IL)

4.1450
+0.0175
+(0.42%)
As of 9:38:09 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Mariano Ucar Angulo Chairman of Directors 1.58M -- --
Mr. Gonzalo Fernández de Valderrama Iribarnegaray Sec. of the Board of Directors 174k -- --

Faes Farma, S.A.

Avenida AutonomIa 10
Leioa, 48940
Spain
34 944 81 83 00 https://faesfarma.com
Sector: 
Healthcare
Full Time Employees: 
1,764

Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

Corporate Governance

Faes Farma, S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 30, 2025 at 7:30 AM UTC

Faes Farma, S.A. Earnings Date

Recent Events

April 12, 2023 at 12:00 AM UTC

Ex-Dividend Date